Free Trial
NYSEAMERICAN:LGL

LGL Group Q2 2024 Earnings Report

LGL Group logo
$7.06 -0.05 (-0.76%)
As of 01:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

LGL Group EPS Results

Actual EPS
$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

LGL Group Revenue Results

Actual Revenue
$0.53 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

LGL Group Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Tuesday, August 13, 2024
Conference Call Time
4:00PM ET

Upcoming Earnings

LGL Group's Q2 2026 earnings is estimated for Thursday, August 13, 2026, based on past reporting schedules, with a conference call scheduled on Monday, August 10, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

LGL Group Earnings Headlines

LGL Group Inc
BNZI posted 169 percent revenue growth - is a turnaround forming
Banzai International (NASDAQ: BNZI) reported full-year 2025 revenue of $12.2 million, up 169% year-over-year, with Q4 growth of 116% and gross margins expanding to 81.9% - hallmarks of a scalable SaaS model gaining traction. With over 150,000 customers, a planned acquisition of ConnectAndSell expected to add roughly $15 million in annual revenue, and a fresh Zacks Rank No. 2 Buy upgrade, institutional confidence is building. A hammer candlestick pattern also suggests potential selling exhaustion and a possible bottom formation.tc pixel
See More LGL Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like LGL Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LGL Group and other key companies, straight to your email.

About LGL Group

LGL Group (NYSEAMERICAN:LGL) Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies. Complementary image analysis software provides tools for cell counting, phenotyping and spatial tissue analysis via customizable algorithms. LGL Group also offers support reagents and consumables designed to streamline sample preparation and ensure reproducible imaging results, as well as service plans for equipment maintenance and software updates.

LGL Group’s products are marketed primarily in North America and Europe through a combination of direct sales and distribution partnerships. The company serves a diverse customer base that includes academic research centers, pharmaceutical and biotechnology organizations, contract research laboratories and hospital pathology departments. By integrating hardware, software and application support, LGL Group aims to address the growing demand for quantitative digital pathology solutions in both drug development and clinical diagnostic settings.

View LGL Group Profile